期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

聚乙二醇化干扰素仪α-2a联合利巴韦林治疗氨基转移酶正常的慢性丙型肝炎 被引量：3

Peginterferon alpha-2a and ribavirin for treating chronic hepa- titis C patients with persistent normal aminotransferase levels
原文传递
导出
摘要 聚乙二醇化干扰素（PEG-IFN）α联合利巴韦林治疗转氨酶升高的慢性丙型肝炎（CHC）效果佳，但对于转氨酶持续正常的CHC，疗效如何尚需积累进一步的临床研究作为循证依据。我们同期对比观察了ALT和AST均正常和均升高的两组CHC患者接受PEG-IFN α-2a联合利巴韦林治疗24周和48周，并随访24周的临床疗效。
作者 姜天俊 范荣 谢阳新 赵鹏 张昕 赵敏 周志平 赫兢
机构地区 解放军第三
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2008年第4期307-308,共2页 Chinese Journal of Hepatology
关键词 肝炎 丙型 慢性 干扰素α 聚乙烯二醇类 Hepatitis C, chronic Interferon alpha-2a Polyethylene glycols
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献7

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量：735
  • 2Afdhal NH. The natural history of hepatitis C. Semin Liver Dis, 2004, 24 Suppl 2: 3-8.
  • 3Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut, 2004, 53: 451-455.
  • 4Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol, 2005, 51: 31-46.
  • 5Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotlansferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis, 2000, 182: 1595-1601.
  • 6Puoti C, Castellacci R, Montagnese F, et al. Histological and virological features and follow-up of hepatitis C virus carders with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carders (ISACC). J Hepatol, 2002, 37:117-123.
  • 7Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol, 2007, 22: 615-633.

二级参考文献15

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献734

同被引文献12

引证文献3

二级引证文献6

中华肝脏病杂志
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部